The Observance Of Clinical Effectiveness Of Independent Developed Prescription-“Decoction For Easing Depression And Dissolving Phlegm” On Depression Patients With Liver Stagnation And Phlegm Accumulation And The Impact On IL-18

Objective: It is to observe the clinical effectiveness of independent developed prescription “Decoction for Easing Depression and Dissolving Phlegm” on patients with depression disorder with liver stagnation and phlegm accumulation and the impact on IL-18.Methods: the experiment was carried out during the period from December 2021 to May 2022,35 subjects were randomly divided into the experimental group and the control group.The subjects of the experimental group received the remedy of phlegm decoction combined with orally taken escitalopram oxalate tablet,and the control group only used orally-taken scitalopram tablet.The general clinical baseline data was recorded,the Hamilton Depression Scale(HAMD-24)and the syndrome integral scale of traditional Chinese medicine displayed better results before and after 4 weeks’ application of the remedy,and the serum IL-18 concentration was determined for further statistical analysis.Results: 1.HAMD score: the results of the test group were significantly different from that of the control group(P<0.05).2.TCM syndrome integral scale: the total efficacy rate of the experimental group was statistically significant difference(P<0.05).3.Serum IL-18 content: the pre-treatment and post-treatment serum IL-18 content of the two groups showed no significant difference(P > 0.05).Conclusion: 1.“Decoction for Easing Depression and Dissolving Phlegm” is beneficial to the clinical treatment of patients with depression disorder with liver stagnation and phlegm accumulation,and can improve their depressive symptoms and clinical syndrome manifestations of traditional Chinese medicine.2.The improvement of depressive symptoms by taking decoction for easing depression and dissolving phlegm and the change of serum IL-18 content are not clear.